Analyzing the atai Life Sciences IPO

Business Trip - A podcast by Greg Kubin & Matias Serebrinsky - Thursdays

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. In this episode, we discuss: How atai went from idea to IPO in 3 yearsAn overview of atai’s drug development programs and enabling technologiesThe platform’s strategy and risks Links to topics in this episode: Atai life sciences Etifoxine Esketamine & arketamine Atai’s S-1 Psychedelic Pharmacist Association Calyx Law Psilocybin Alpha, Noeti...

Visit the podcast's native language site